Eye Disease Archives

News and Trends 14 Sep 2022

SparingVision raises €75M for genomic medicines for ocular diseases

SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

Horizone Therapeutics, Eye disease, eye, eyes

News and Trends 9 Sep 2022

Improved vision with less eye injections for patients after primary endpoints met in trials

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

September 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced the news today (August 29) that the authorization was granted to Ranivisio, which is a biosimilar to Lucentis, a ranibizumab injection. Positive opinion: CHMP The […]

August 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Jul 2022

New drug application for treatment of dry eyes disease submitted to FDA

A treatment for dry eye symptoms associated with Meibomian gland dysfunction (MGD) has been submitted under a New Drug Application (NDA) and will be considered by the US Food and Drug Administration. The application was submitted at the end of last month (June) by the Canada-based global eye health company, Bausch and Lomb Corporation, and […]

July 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

BRIM Biotechnology enters OTC trading in Taiwan

BRIM Biotechnology, Inc.has entered OTC (over the counter) trading in Taiwan. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. The company’s current paid-in capital is approximately $23 million. BRIM has several novel drug products in its pipeline, all underpinned by […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Jun 2022

Sling Therapeutics emerges with $35M to tackle thyroid eye disease

Michigan-based biopharma company Sling Therapeutics, Inc. has launched, with $35 million in series A financing led by TPG’s The Rise Fund. The company is focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The funds support a phase 2b clinical trial evaluating its investigational drug, linsitinib. “We […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Mar 2022

Europe’s Ophthalmology Scene Stays Hot for Biotech Funding

Ophthalmology-focused startups had a record year for venture capital funding in 2021. Impressive Series A rounds and collaborations hint at a continuing upward trend for the field in 2022. Biotech companies researching treatments for ophthalmological conditions experienced a splurge of venture capital (VC) funding in 2021, with the total more than trebling the haul from […]

March 3, 2022 - 5 minutesmins - By Jonathan Smith

In Depth 10 Mar 2021

Can Gene Therapy Cure Blindness?

Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic blindness. Luxturna became the first gene therapy for inherited blindness to receive FDA approval back in 2017. About a year later, the therapy was approved […]

March 10, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 May 2020

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […]

May 20, 2020 - 3 minutesmins - By Helen Albert

News and Trends 20 Jan 2020

Medical Gel Prepares to Enter Clinical Trials for Replacing Corneal Transplants

An international collaboration involving researchers in Europe, Asia, and North America has begun preparations for testing in humans a therapeutic gel that could replace the need for corneal transplants for the treatment of blindness. Corneal transplants are the most common treatment for blindness caused by corneal injury. However, donor shortages and high costs make it […]

January 20, 2020 - 2 minutesmins - By Jonathan Smith

Startup Scout 10 Jan 2020

This Biotech Makes Easily Implantable Artificial Cornea Transplants

CorNeat Vision, based in Israel, is developing an easily-implantable and affordable artificial cornea that could one day replace donor corneas in people needing transplants and therefore address the shortage of donor tissue. Mission: To develop a cornea made from plastic that is easier to supply and implant than donor corneas. The implant is also designed […]

January 10, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Sep 2019

Gyroscope Targets Age-Related Blindness with €55M Series B

UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […]

September 3, 2019 - 2 minutesmins - By Helen Albert

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eye Disease

SparingVision raises €75M for genomic medicines for ocular diseases

Improved vision with less eye injections for patients after primary endpoints met in trials

Marketing authorization granted for treatment of serious retinal diseases

New drug application for treatment of dry eyes disease submitted to FDA

BRIM Biotechnology enters OTC trading in Taiwan

Sling Therapeutics emerges with $35M to tackle thyroid eye disease

Europe’s Ophthalmology Scene Stays Hot for Biotech Funding

Can Gene Therapy Cure Blindness?

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

Medical Gel Prepares to Enter Clinical Trials for Replacing Corneal Transplants

This Biotech Makes Easily Implantable Artificial Cornea Transplants

Gyroscope Targets Age-Related Blindness with €55M Series B

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!